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SUMMARY
Limited studies exist regarding whether incorporating micronutrient supplements during
tuberculosis (TB) treatment may improve cell-mediated immune response. We examined the
effect of micronutrient supplementation on lymphocyte proliferation response to mycobacteria
or T-cell mitogens in a randomized trial conducted on 423 patients with pulmonary TB.
Eligible participants were randomly assigned to receive a daily dose of micronutrients
(vitamins A, B-complex, C, E, and selenium) or placebo at the time of initiation of TB
treatment. We found no overall effect of micronutrient supplements on lymphocyte proliferative
responses to phytohaemagglutinin or purified protein derivatives in HIV-negative and
HIV-positive TB patients. Of HIV-negative TB patients, the micronutrient group tended to
show higher proliferative responses to concanavalin A than the placebo group, although the
clinical relevance of this finding is not readily notable. The role of nutritional intervention
in this vulnerable population remains an important area of future research.
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INTRODUCTION
Tuberculosis (TB) continues to be a major cause of
illness and mortality worldwide [1]. HIV-infected
individuals have a high risk of developing clinical
TB, and HIV has fuelled the TB epidemic in sub-
Saharan Africa. TB patients often suffer from mal-
nutrition, especially micronutrient deficiencies [2, 3].
Studies have shown that TB patients have a high
prevalence of deficiencies in vitamins A, B-complex,
C, E, and selenium [2].
Host defence against Mycobacterium tuberculosis
infection requires cell-mediated immunity, which
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involves coordination of macrophages and T-cell
lymphocytes. Patients with a dual burden of myco-
bacterial infection and micronutrient deficiencies
may have impaired cell-mediated immune response.
However, a previous review concluded that there is
insufficient evidence for a beneficial effect of multiple
micronutrient supplements on clinical outcomes in TB
patients [4]. We have previously reported that micro-
nutrient supplementation significantly decreased the
risk of early TB recurrences in Tanzania [5]. Under-
standing potential mechanisms mediating such ben-
eficial effects is important. In this paper, we examine
the effect of micronutrient supplements on lympho-
cyte proliferation response to mycobacteria or T-cell
mitogens, markers of cell-mediated immune function,
in a randomized trial conducted on patients with pul-
monary TB.
METHODS
Study design and population
From April 2000 to April 2005, adults with pulmon-
ary TB were enrolled in a randomized, double-blind,
placebo-controlled trial to examine the effect of
micronutrient supplements on TB treatment outcomes
and mortality. Details of the study design have been
published previously [5]. Participants were recruited
from five outpatient TB clinics in Dar es Salaam,
Tanzania. Eligible participants were men and non-
pregnant women aged between 18 and 65 years who
had at least two positive sputum smears for
acid-fast bacilli (AFB). Patients with a Karnofsky
performance score of <40% or haemoglobin concen-
tration of <7·0 g/dl were excluded from the study.
HIV testing was conducted using two sequential
enzyme-linked immunosorbent assays (ELISA) in an
alternative confirmatory strategy and discrepant
results were resolved by Western blot assay. Partici-
pants were stratified by HIV status and randomly
assigned to receive a daily dose of micronutrients
(5000 IU retinol, 20 mg vitamin B1, 20 mg vitamin
B2, 100mg niacin, 25 mg vitamin B6, 50 μg vitamin
B12, 500mg vitamin C, 200 mg vitamin E, 0·8 mg
folic acid, 100 μg selenium) or placebo at the time of
initiation of TB treatment. As recommended by the
Tanzania National TB and Leprosy Programme at
the time of the study, patients received a daily com-
bination of rifampicin, isoniazid, pyrazinamide, and
ethambutol at the health facility under direct obser-
vation of a healthcare worker for the first 2 months.
In the subsequent 6 months, patients self-administered
isoniazid and ethambutol at home. Antiretroviral
therapy was not available to most HIV-positive par-
ticipants at the time of the study in Tanzania.
At the baseline visit, trained research assistants
obtained information about demographic and socio-
economic characteristics. Follow-up was conducted
every month at the study clinics where research nurses
inquired about the health of the patient. A physician
carried out a complete physical examination every
3 months. Sputum for AFB smears and cultures was
collected. A blood sample was obtained to measure
haemoglobin concentrations and CD4+, CD8+, and
CD3+ T cells using the FACScount or FACScan
systems (BD Biosciences, USA). HIV viral load was
also measured using the Roche Amplicor v. 1.5 assay
(Roche Diagnostics, USA). The HIV disease stage
was assessed according to the World Health Organiz-
ation (WHO) staging system [6].
The study protocol was approved by the Instit-
utional Review Boards at the Muhimbili University
of Health and Allied Sciences, the Tanzanian
National AIDS Control Program, and the Harvard
School of Public Health. All patients provided written
informed consent to participate in the trial.
Assessment of lymphocyte proliferation assay response
In vitro lymphocyte proliferation is frequently used as
a marker for cell-mediated immune function. Lympho-
cyte proliferation was measured by [3H]thymidine
incorporation after stimulation with T-cell mitogens
or TB antigens using the whole-blood culture method.
For each patient, 5 ml blood was collected into
heparin-containing Vacutainers for the whole-blood
assay. The blood was diluted at 1:10 with complete
Roswell Park Memorial Institute Medium (RPMI
1640 culture medium supplemented with 100 U/ml
penicillin, 100 μg/ml streptomycin, 2 mmol/l L-glut-
amine, 25 mmol/l Hepes). Diluted blood was dis-
tributed into 96-well tissue culture plates, and then
stimulated with concanavalin A (ConA) at 5, 25, and
50 mg/l, phytohaemagglutinin (PHA) at 2, 10, and
50 mg/l, or purified protein derivatives (PPD) at 2, 5,
and 20 mg/l. The plates were incubated for 72 h at
37 °C in a 5% CO2 humidified atmosphere. Cultures
were pulsed with [3H]thymidine during the final 4 h
of incubation. At the end of incubation, the plates
were first frozen at –70 °C overnight and then stored
at –20 °C before harvest. After 1 h of incubation at
37 °C in trypsin/EDTA solution, cells were harvested
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using an automatic harvester. Cell proliferation was
quantified as the amount of [3H]thymidine incorpor-
ation into DNA as determined by a liquid scintillation
counter. The results of in vitro stimulation of lympho-
cytes were reported as counts per minute (cpm). We
report results generated with use of the optimal con-
centration for each stimulant: 25 mg/l ConA, 10mg/l
PHA and 5mg/l PPD. Similar results were found
when other concentrations were used for stimulation
(data not shown).
Statistical analysis
Of 887 adults with pulmonary TB (416 HIV-negative
and 471 HIV-positive patients) enrolled in the trial,
at least one measurement of lymphocyte proliferation
at 2 or 8 months was made for 423 patients (267 HIV-
negative and 156 HIV-positive patients). Due to logis-
tics issues, lymphocyte proliferation could not be
measured in all participants, especially HIV-positive
patients. We compared the distribution of baseline
characteristics between treatment groups within the
strata of HIV status by using the Wilcoxon rank
sum test for continuous variables and the χ2 test for
categorical variables. An intention-to-treat analysis
was performed. To examine the effect of micronutrient
supplements on lymphocyte proliferative responses,
we conducted an analysis of parallel mean response
profiles with adjustment for baseline using generalized
linear models for repeated measurements [7]. The
robust empirical variance structure was used. All stat-
istical analyses were conducted using SAS v. 9.1 (SAS
Institute Inc., USA).
RESULTS
We examined the characteristics of 423 TB patients
with the measurement of lymphocyte proliferative
responses by treatment arms within strata of HIV sta-
tus (Table 1). Patients’ baseline characteristics were
similar between micronutrient and placebo groups.
We found no significant effect of micronutrient supple-
ments on lymphocyte proliferative responses to T-cell
mitogen (10 mg/l PHA) or mycobacterial antigens
(5 mg/l PPD) during TB treatment in HIV-negative
and HIV-positive TB patients (Table 2). Of HIV-
negative TB patients, the micronutrient group tended
to show higher proliferative responses to T-cell mito-
gen (25 mg/l ConA) than the placebo group (P=
0·04), although the effect was limited to 2 month.
DISCUSSION
We found no overall effects of supplementation
with micronutrients at multiples of the recommended
dietary allowance on lymphocyte proliferative re-
sponses to T-cell mitogens or mycobacterial antigens
in HIV-negative and HIV-positive TB patients.
Of HIV-negative TB patients, the micronutrient
group tended to show higher proliferative responses
Table 1. Baseline characteristics of tuberculosis patients
Characteristics









Female 36 (28·1%) 33 (23·7%) 0·35 29 (40·3%) 39 (46·4%) 0·44
Age (years) 29·2±9·2 30·8±9·2 0·06 33·3±6·5 33·2±9·3 0·45
Density of acid-fast bacilli in the smear 0·22 0·42
<1/field 12 (9·4%) 6 (4·3%) 15 (20·8%) 21 (25·3%)
1–10/field 11 (8·6%) 10 (7·2%) 14 (19·4%) 10 (12·1%)
>10/field 105 (82·0%) 123 (88·5%) 43 (59·7%) 52 (62·7%)
Karnofsky score, <70% 13 (10·2%) 11 (7·9%) 0·50 7 (9·7%) 11 (13·1%) 0·51
Body mass index (kg/m2) 18·8±2·5 19·0±2·5 0·40 20·1±2·9 19·8±3·0 0·33
Mid-upper arm circumference (cm) 22·8±2·5 23·4±2·5 0·13 24·0±2·4 23·5±2·9 0·09
Haemoglobin (g/dl) 11·0±1·4 11·2±1·8 0·66 10·1±1·6 10·3±1·6 0·44
CD4+ count (cells/mm3) 707±257 704±262 0·99 329±209 387±261 0·28
CD8+ count (cells/mm3) 446±213 426±193 0·52 894±417 833±493 0·22
CD3+ count (cells/mm3) 1211±439 1186±418 0·88 1292±560 1290±677 0·60
Log10 viral load (copies/mm
3) — — — 4·45±0·88 4·32±1·02 0·61
Values are mean±S.D., otherwise n (%).
The Wilcoxon rank sum test was used to compare continuous variables and the χ2 test was used for categorical variables.
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to ConA than the placebo group, although the clinical
relevance of this finding is not readily notable. In this
trial, micronutrient supplementation was found to sig-
nificantly decrease the risk of early TB recurrence by
45% in all TB patients and increased CD4+ cell
counts in HIV-negative patients [5]. Supplementation
also reduced the incidence of peripheral neuropathy
by 57% in all patients. Although unexpected, our
overall lack of effects on lymphocyte proliferation
could be due to a number of reasons. We only assessed
these immune parameters twice, at 2 and 8 months,
and detection of an effect may have required earlier
assessments, particularly during the first 2 months of
the anti-TB treatment period when active clearance
of M. tuberculosis occurs. Furthermore, we did not
measure other markers such as the production of cyto-
kines, including interferon-γ and tumour necrosis
factor-α, which may have more fully captured the
effects of micronutrient supplementation. The lack
of findings could also be due to measurement error
during laboratory assays thereby biasing any potential
association towards the null. Our results are unlikely
to be due to lack of adherence, because our study
had high follow-up rates and high compliance with
the study regimen. Additionally, adequate dosages
of micronutrient supplements were provided in this
trial.
Contrary to our findings, previous studies have
addressed the important role of vitamins on immune
responses to mycobacterial infection. Vitamin A
plays a crucial role in the cell-mediated response and
the lymphocyte proliferative response is up-regulated
by retinoic acid receptors [8, 9]. Antioxidants, such
as vitamins C and E, and selenium may suppress re-
active oxygen species produced by mycobacteria and
prevent tissue injury and inflammation. Oxidative
stress and excessive inflammatory responses may sup-
press T-cell function. An in vitro study using periph-
eral blood mononuclear cells from TB patients
found that vitamin E enhances lymphocyte prolifer-
ation in response to PPD [10]. Vitamin B6 deficiency
has been associated with decreased lymphocyte re-
sponsiveness to T-cell mitogen and decreased natural
killer cell activities [5, 11, 12].
Several limitations should be noted. Supplements in
our study did not include zinc or vitamin D, and these














Baseline 4795±428 5187±484 — 3110±779 3048±602 —
2 months 7667±732 5890±615 0·04 2446±381 2814±367 0·69
8 months 4285±586 5534±761 0·55 2258±673 1733±355 0·70
0·04 0·61
PHA (10mg/l)
Baseline 13053±1188 11954±1108 — 5885±1300 7243±1036 —
2 months 13352±1267 11896±1158 0·81 6689±1189 7826±740 0·91
8 months 6248±891 7097±910 0·53 5336±1106 2994±472 0·11
0·62 0·15
PPD (5mg/l)
Baseline 752±118 698±72 — 800±291 646±197 —
2 months 1333±274 860±102 0·10 674±188 941±210 0·34
8 months 521±148 585±126 0·93 523±194 993±311 0·20
0·24 0·42
Values given are mean±S.E.
*Whole blood was stimulated in vitro with T-cell mitogens, concanavalin A (ConA) and phytohaemagglutinin (PHA), or
mycobacterial antigens (purified protein derivative; PPD) and measured by [3H]thymidine incorporation. Values are
expressed as counts per minute (cpm).
†Treatment effects at 2 or 8 months. P value was obtained from an analysis of parallel mean response profiles with
adjustment for baseline response. We used the general linear model for repeated measurements with the robust empirical
variance.
‡Overall treatment effects.
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nutrients play important role in improving immune
functions and TB treatment outcomes [4]. Vitamin
D induces antimycobacterial activity in macrophages,
and observational studies have shown that low serum
vitamin D levels increase the risk of active TB [13].
It is uncertain whether relatively low lymphocyte pro-
liferative responses in our study compared to previous
studies may be due to the study population or lab-
oratory method. We used the whole-blood culture
method instead of the isolated peripheral blood mono-
nuclear cells method, because whole-blood culture re-
quires only a small amount of blood and is much less
labour intensive. At the time of the study, antiretroviral
therapy was not available to most HIV-positive par-
ticipants in Tanzania. Therefore, our findings need
to be confirmed under concomitant treatment with
antiretroviral therapy in HIV-positive patients.
In conclusion, we found no overall effects of micro-
nutrient supplementation on T-cell-mediated immune
responses in patients treated for pulmonary TB.
Micronutrient supplements have been found to reduce
TB recurrence in TB patients and the role of nutri-
tional intervention in this vulnerable population
remains an important area of research [2]. Additional
studies are needed to understand the interactions
between nutrition, immune function, and clinical out-
comes in TB patients.
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